×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ALT – altimmune, inc. (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ALT
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/15
11:11 am
alt
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024 [Yahoo! Finance]
Low
Report
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024 [Yahoo! Finance]
11/15
11:00 am
alt
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024
Low
Report
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024
11/14
08:15 am
alt
Altimmune, Inc. (NASDAQ: ALT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
High
Report
Altimmune, Inc. (NASDAQ: ALT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
11/13
02:26 am
alt
Altimmune Inc (ALT) Q3 2024 Earnings Call Highlights: Strategic FDA Alignment and Expanding ... [Yahoo! Finance]
Medium
Report
Altimmune Inc (ALT) Q3 2024 Earnings Call Highlights: Strategic FDA Alignment and Expanding ... [Yahoo! Finance]
11/12
07:31 am
alt
Altimmune, Inc. (NASDAQ: ALT) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $26.00 price target on the stock.
High
Report
Altimmune, Inc. (NASDAQ: ALT) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $26.00 price target on the stock.
11/12
07:00 am
alt
Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update
High
Report
Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update
11/11
07:30 am
alt
Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/11
07:30 am
alt
Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer
Medium
Report
Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Symbol
Headline
Impact
11/14
11:59 am
alt
Form SC 13G/A Altimmune, Inc. Filed by: AMERIPRISE FINANCIAL INC
Medium
Report
Form SC 13G/A Altimmune, Inc. Filed by: AMERIPRISE FINANCIAL INC
11/12
04:51 pm
alt
Form 4 Altimmune, Inc. For: Nov 11 Filed by: WEAVER GREGORY L
Low
Report
Form 4 Altimmune, Inc. For: Nov 11 Filed by: WEAVER GREGORY L
11/12
04:50 pm
alt
Form 3 Altimmune, Inc. For: Nov 11 Filed by: WEAVER GREGORY L
Low
Report
Form 3 Altimmune, Inc. For: Nov 11 Filed by: WEAVER GREGORY L
11/12
04:07 pm
alt
Form 10-Q Altimmune, Inc. For: Sep 30
Low
Report
Form 10-Q Altimmune, Inc. For: Sep 30
11/12
09:33 am
alt
Form 8-K Altimmune, Inc. For: Nov 12
High
Report
Form 8-K Altimmune, Inc. For: Nov 12
11/12
09:21 am
alt
Form 8-K Altimmune, Inc. For: Nov 11
High
Report
Form 8-K Altimmune, Inc. For: Nov 11
10/17
11:17 am
alt
Form SC 13G/A Altimmune, Inc. Filed by: STATE STREET CORP
Low
Report
Form SC 13G/A Altimmune, Inc. Filed by: STATE STREET CORP
10/16
04:21 pm
alt
Form SC 13G/A Altimmune, Inc. Filed by: MILLENNIUM MANAGEMENT LLC
Low
Report
Form SC 13G/A Altimmune, Inc. Filed by: MILLENNIUM MANAGEMENT LLC
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
2/28
Altimmune Completes First Development Milestone Toward a Single-Dose Intranasal COVID-19 Vaccine
29.8%
3/4 Altimmune (ALT) Presenta At Cowen Health Care Conference - Slideshow [Seeking Alpha] 18.2%
3/27 Form 8-K Altimmune, Inc. For: Mar 27 7.5%
6/12 Form 8-K Altimmune, Inc. For: Jun 10 5.5%
2/4 Form 4 Altimmune, Inc. For: Jan 31 Filed by: Roberts M Scot 3.4%
5/15 Altimmune, Inc. (ALT) CEO Vipin Garg on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] 1.9%
11/21 Altimmune to Host Key Opinion Leader Call on ALT-801 for the Treatment of NASH 1.8%
4/8 Form 8-K Altimmune, Inc. For: Apr 02 1.8%
6/12 Altimmune Appoints Will Brown as Chief Financial Officer 1.7%
8/14 Form S-8 Altimmune, Inc. 1.5%
3/4 Altimmune (ALT) Presenta At Cowen Health Care Conference - Slideshow [Seeking Alpha] 18.2%
3/27 Form 8-K Altimmune, Inc. For: Mar 27 7.5%
6/12 Form 8-K Altimmune, Inc. For: Jun 10 5.5%
2/4 Form 4 Altimmune, Inc. For: Jan 31 Filed by: Roberts M Scot 3.4%
5/15 Altimmune, Inc. (ALT) CEO Vipin Garg on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] 1.9%
11/21 Altimmune to Host Key Opinion Leader Call on ALT-801 for the Treatment of NASH 1.8%
4/8 Form 8-K Altimmune, Inc. For: Apr 02 1.8%
6/12 Altimmune Appoints Will Brown as Chief Financial Officer 1.7%
8/14 Form S-8 Altimmune, Inc. 1.5%
TOP News Decliners
3/9
Thinking about buying stock in Aurora Cannabis, Altimmune, Chesapeake Energy Corp, Nokia, or Sprint?
-20.8%
7/9 Altimmune Signs Definitive Agreement to Acquire Spitfire Pharma, Inc. Adding NASH Drug Candidate to Portfolio -14.2%
3/30 Altimmune and the University of Alabama at Birmingham to Collaborate on Development of Single-Dose, Intranasal COVID-19 Vaccine -13.7%
3/27 Form 8-K Altimmune, Inc. For: Mar 27 -13.4%
1/23 Altimmune Announces Positive Results for ALT-702 in Preclinical Model of Colorectal Cancer -12.6%
3/3 Form 4 Altimmune, Inc. For: Feb 29 Filed by: Garg Vipin K -12.0%
8/21 Form 8-K Altimmune, Inc. For: Aug 20 -11.7%
11/13 Altimmune Announces Third Quarter 2019 Financial Results and Provides a Business Update -10.1%
6/10 Altimmune Announces Successful Pre-IND Meeting with FDA -10.0%
6/5 Altimmune Announces Important Additions to its Patent Portfolio for HepTcell and ALT-702 Programs -9.6%
7/9 Altimmune Signs Definitive Agreement to Acquire Spitfire Pharma, Inc. Adding NASH Drug Candidate to Portfolio -14.2%
3/30 Altimmune and the University of Alabama at Birmingham to Collaborate on Development of Single-Dose, Intranasal COVID-19 Vaccine -13.7%
3/27 Form 8-K Altimmune, Inc. For: Mar 27 -13.4%
1/23 Altimmune Announces Positive Results for ALT-702 in Preclinical Model of Colorectal Cancer -12.6%
3/3 Form 4 Altimmune, Inc. For: Feb 29 Filed by: Garg Vipin K -12.0%
8/21 Form 8-K Altimmune, Inc. For: Aug 20 -11.7%
11/13 Altimmune Announces Third Quarter 2019 Financial Results and Provides a Business Update -10.1%
6/10 Altimmune Announces Successful Pre-IND Meeting with FDA -10.0%
6/5 Altimmune Announces Important Additions to its Patent Portfolio for HepTcell and ALT-702 Programs -9.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: